BioCryst Pharmaceuticals BCRX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- BioCryst Pharmaceuticals (BCRX) reported comprehensive income (loss), net of tax, attributable to parent of -$722.22M in Q1 2026.
- How has BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 297309.1% year-over-year, from $243K to -$722.22M.
- What is the long-term trend for BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 9.4% compound annual growth rate (CAGR), from -$183.89M to $262.98M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- The sum of net income and other comprehensive income, representing the total change in equity from all sources during the period. It serves as a holistic indicator of the company's overall financial health and value creation.